BioVentix revenue, earnings rise in first half
25th Mar 2024 12:17
(Sharecast News) - Monoclonal antibody specialist BioVentix reported a 13% rise in first-half revenue on Monday, to £6.7m, compared to £5.9m in the prior year.
Read moreSunday share tips: Octopus Renewables Infrastructure Trust, Bioventix
19th Nov 2023 21:24
(Sharecast News) - The Financial Mail on Sunday's Midas column tipped the Octopus Renewables Infrastructure Trust to readers, pointing out its 7% dividend yield and the current valuation of its shares.
Read moreBioVentix revenue, profits improve in full-year results
24th Oct 2022 11:55
(Sharecast News) - Diagnostic monoclonal antibody specialist BioVentix reported a 7% improvement in revenue in its full-year results on Monday, to £11.72m.
Read moreBioventix hikes interim dividend after revenue falls
28th Mar 2022 11:48
(Sharecast News) - Monoclonal antibody developer and supplier Bioventix reported an 8% fall in revenue in its first half on Monday, to £4.7m.
Read moreBioventix revenue rises in tougher first half
29th Mar 2021 08:58
(Sharecast News) - Diagnostic antibody developer Bioventix reported a 1.3% improvement in revenue in its first half on Monday, to £5.2m.
Read moreBioventix appoints Bruce Hiscox as chief financial officer
1st Jul 2020 09:40
(Sharecast News) - Antibodies developer Bioventix named Bruce Hiscock would join the group its new chief financial officer on Wednesday.
Read moreBioventix full-year revenue and profits improve
21st Oct 2019 11:33
(Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue for the year on Monday, to £9.3m.
Read moreVitamin D antibodies drive first-half growth at Bioventix
29th Mar 2019 08:31
(Sharecast News) - Monoclonal antibodies developer and supplier Bioventix reported a 24% improvement in its normalised revenue in its half-year report on Friday, to £4.4m.
Read moreBioventix posts healthy profits, ups dividend; warns of plateauing vit-D sales
8th Oct 2018 12:09
(Sharecast News) - Aim's Bioventix announced Monday it would pay a special dividend after a strong year of revenue and profit growth - but also sounded a warning over one of its key revenue streams.
Read moreBioventix profits will beat forecasts, boost eyed from Siemens link
22nd Aug 2016 09:34
(ShareCast News) - Bioventix revealed that revenues and profits will be ahead of expectations for the full year thanks to currency effects and continued demand for its monoclonal antibodies. Revenue for the year to 30 June will come in at £5.3m, which is at least 11% ahead of the forecast £4.8m and
Read moreBioventix signs deal to end dispute with Diasource
21st Aug 2014 09:44
Bioventix, an AIM-listed company focused on the development of anti-bodies, has signed an agreement to license intellectual property owned by Belgian company Diasource ImmunoAssays. The two groups had been in dispute over one of Diasource's European patents, but said a licence agreement was "the pr
Read more